HLB Life Science Co Ltd

HLB Life Science has a liquidity risk profile marked by a current ratio of 0.58 and negative free cash flow of -120.6 billion KRW, indicating short-term financial strain. The company's price-to-book ratio of 1.74 and debt-to-equity ratio of 0.54 suggest moderate leverage but no immediate dilution pressure. Profitability metrics are severely negative, with a return on equity of -33.56% and return on assets of -20.87%, far below the typical thresholds for pharmaceutical firms. The operating margin is -53.4%, and the net margin is -218.2%, both of which are well below industry norms. The company's revenue is concentrated across four segments: Pharmaceutical Distribution, Energy Business, Bio Development, and Other Business. The pharmaceutical distribution segment is a key revenue driver, but the energy and bio development segments are likely underperforming given the overall negative operating income. HLB Life Science's growth trajectory is negative, with a net income decline of 99.8 billion KRW in the latest period. The company's revenue of 45.8 billion KRW is insufficient to cover operating expenses, and there is no indication of near-term improvement in the outlook. The company faces a high risk of liquidity stress due to negative operating cash flow and free cash flow. The risk assessment flags net cash as negative after subtracting total debt, and the liquidity risk is rated as medium. The dilution risk is low, but the company's capital structure is vulnerable to further deterioration. Recent filings and transcripts indicate no material events that would alter the company's financial trajectory. The absence of positive developments in the pharmaceutical or energy segments suggests continued operational challenges.